Dr. Chethan Ramamurthy, MD
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Medical school
- Baylor College of Medicine (2012)
- Years since graduation
- 14
- In the NPI registry since
- 2012
- Medicare patients seen, 2024
- 12
Licensed in Texas since 2018, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2012Medical school: Baylor College of Medicine
- 2012Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
TX license R8082 (first issued 2018; active) -
Internal Medicine Physician
TX license R8082 (first issued 2018; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University Health System San Antonio, TX
- Ut Health San Antonio Multispecialty & Research Ho San Antonio, TX
Medical groups
- University of Texas Health Science Center at San Antonio (1,297 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 12
- Services billed
- 56
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Injection, ondansetron hydrochloride, per 1 mg | 476 | 25 |
| Injection, dexamethasone sodium phosphate, 1 mg | 396 | 25 |
| Established patient office or other outpatient visit, 30-39 minutes | 111 | 74 |
| Injection of additional new drug or substance into vein | 81 | 34 |
| Administration of chemotherapy into vein, 1 hour or less | 61 | 48 |
| Established patient office or other outpatient visit, 40-54 minutes | 56 | 46 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 45 | 28 |
| Administration of chemotherapy into vein, each additional hour | 21 | 13 |
| Injection of drug or substance under skin or into muscle | 19 | 15 |
| Injection, diphenhydramine hcl, up to 50 mg | 17 | 15 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $338 in research payments for these studies, mostly to the institutions running them.
- A Phase 3, Randomized, Study of Neoadjuvant and Adjuvant Nivolumab Plus Bempegaldesleukin (NKTR214), Versus Nivolumab Alone Versus Standard of Care in Participants With MuscleInvasive Bladder Cancer (MIBC) Who Are Cis…
E.r. Squibb & Sons, L.l.c.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.